Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Rodenticides Stories

2010-03-08 13:16:42

Children with serious intestinal problems have to be fed intravenously. There moreover, exist systems that enable intravenous feeding to be carried out at home. Mr Iñaki Irastorza, pediatrician at the Cruces hospital in Bilbao, spent some 15 years analyzing how serious intestinal problems in children were treated at the Great Ormond Street Children's Hospital in London. With the gathered data he has presented a highly novel PhD thesis at the University of the Basque...

2009-10-15 11:15:00

National Trauma Databank researchers find elderly patients more vulnerable to problems CHICAGO, Oct. 15 /PRNewswire-USNewswire/ -- A common drug used for preventing heart attacks and blood clots may also cause problems for individuals who suffer some form of trauma, particularly elderly patients, according to a study presented today at the 2009 Clinical Congress of the American College of Surgeons. The study findings could have implications for how doctors prescribe warfarin as use of...

2009-07-15 07:30:00

BOSTON and EDISON, N.J., July 15 /PRNewswire/ -- A sub-analysis of a Phase IIb multinational study(1) with edoxaban(2) - an investigational oral Factor Xa inhibitor - provides insights into why patients with non-valvular atrial fibrillation (AF) receiving edoxaban once daily (QD) experienced fewer bleeding events than patients given edoxaban twice a day (BID). The analysis finds that bleeding associated with edoxaban is most closely correlated with minimum concentration levels of the drug...

2009-03-20 15:20:00

Researchers at Uppsala University, together with colleagues at the Karolinska Institute and the Sanger Institute, have now found all the genes the determine the dosage of the blood-thinning drug warfarin. The findings are published in the scientific journal PLoS Genetics. "We have previously studied selected genes that can affect warfarin treatment. Now that we have gone in and scanned the entire genome, we see that the two most important genes are among those we previously singled out," says...

e29283798612de911f6ea690fce79de31
2009-02-19 14:31:06

A new formula that involves gene testing could equip doctors with a better means of gauging the dosage of the common blood-thinning drug warfarin, according to a new large-scale study. Warfarin is one of the most widely prescribed drugs in the world "“ an estimated 2 million Americans with heart conditions or other risk factors begin taking the drug each year "“ but doctors currently use a method of trial and error to determine how much a patient should be taking. This method...

2009-01-20 10:07:10

New analyses led by the University of Cincinnati (UC) show that genetic testing used to guide initial dosing of the blood-thinner warfarin may not be cost-effective for typical patients with atrial fibrillation but may be for patients at higher risk for major bleeding. This study is being published in the Jan. 20, 2009, edition of Annals of Internal Medicine. Warfarin is commonly prescribed to prevent blood clotting, particularly for patients with atrial fibrillation"”a type of abnormal...

2008-12-22 11:25:36

Researchers from Boston University School of Medicine (BUSM) have determined the optimal dose-management strategy to derive maximal benefit from warfarin therapy and improve patient outcomes. Results of the study appear online in the December 2008 issue of the Journal of Thrombosis and Haemostasis. Warfarin is highly effective to prevent strokes, treat venous thromboembolism and for other conditions. Numerous studies have focused on the underutilization of warfarin for patients with atrial...

2008-11-03 09:00:39

ARYx Therapeutics Inc. (NASDAQ:ARYX), a biopharmaceutical company, today announced it has completed enrollment in EmbraceAC, a Phase 2/3 double-blind clinical trial comparing its oral anticoagulation therapy, ATI-5923, against the leading anticoagulant agent, warfarin. The purpose of the trial is to evaluate whether ATI-5923 is superior to warfarin in its ability to maintain patients within a target therapeutic range of the level of anticoagulation as measured by INR (International Normalized...

2008-10-30 09:00:40

SeraCare Life Sciences, Inc. (NASDAQ: SRLS) launched the Company's anticipated genetic controls business with the introduction of two new products at the Association for Molecular Pathology 2008 Annual Meeting. Initial products launched include ACCURUN(R) 601 controls for diagnostic testing of warfarin sensitivity and ACCURUN(R) 610 controls for thrombophilia testing, which were developed internally by SeraCare. Additionally, the Company announced that it has entered into an exclusive...

2008-10-28 12:30:00

U.S. scientists say they're using DNA extracted from saliva to customize prescriptions and solve dosing problems that often confound doctors and patients. By using DNA to customize a prescription, researchers at Temple University's School of Pharmacy hope to prevent adverse drug reactions. At the top of the list of problem drugs is warfarin (Coumadin), the most widely prescribed anticoagulant. The researchers say they're trying to find the correlation between genotypes and the correct...